Latest stories on CNTX
Oil tops $90 as Middle East fighting escalates
Axios44 · neutralgeo/war
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CNTX Stock News
StockTitan50 · neutralgeneral
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart50 · neutralgeneral
WitnessAI Unveils NER-D, a Breakthrough AI Model for Context-Aware Sensitive-Data Detection
PR Newswire63 · neutralproduct/pr
Oklo’s Advanced Reactor Ambitions Highlighted Amid US Push for Domestic Uranium Supply
MarketChameleon63 · neutralproduct/pr
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes | CNTX Stock News
StockTitan63 · neutralgeneral
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish
Yahoo Top56 · neutralanalyst
Context Therapeutics Inc. (CNTX) files 8-K
SEC 8-K50 · neutralgeneral
Convr® Makes the Industry's Only Commercial P&C Risk Context Engine Available to AI Agents via Model Context Protocol (MCP)
PR Newswire63 · neutralproduct/pr
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip
Stocktwits News48 · neutralproduct/pr
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
TipRanks67 · bullishproduct/pr
Context Therapeutics Inc. (CNTX) files 8-K
SEC 8-K50 · neutralgeneral
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CNTX Stock News
StockTitan50 · neutralgeneral
Ambition Launches MCP Integration, Enabling Revenue Organizations to Maximize Frontline Clarity and Efficiency
PR Newswire59 · neutralproduct/pr
BridgeWise's Context Analytics Launches First-of-Its-Kind Podcast Sentiment Analysis and Scoring for Investors
Morningstar56 · neutralproduct/pr
Context Therapeutics to Present at the Jefferies Global Healthcare Conference | CNTX Stock News
StockTitan55 · neutralgeneral
2 AI Stocks Hugely Benefit From 'RAMpocalypse'
Seeking Alpha63 · neutralproduct/pr
BCAB’s CT-202 Milestone Buyout: Full Economic Rights Handed to Context Therapeutics in $6.5M Deal
MarketChameleon63 · neutralm&a